- New data from Novartis shows promising results for Leqvio® in cholesterol management
- Leqvio® effectively lowers LDL-C levels when combined with statin therapy
- Significant improvements observed in patients with atherosclerotic cardiovascular disease
Basel, Switzerland — Novartis data showed Sunday that Leqvio reduces LDL-C in ASCVD patients when added early after statin therapy.
This latest study, focused on patients with atherosclerotic cardiovascular disease (ASCVD), reveals significant reductions in low-density lipoprotein cholesterol (LDL-C), offering hope for those not achieving desired results with statin therapy alone.
Presented at the prestigious 2024 American College of Cardiology’s Annual Scientific Session & Expo and published simultaneously in the Journal of the American College of Cardiology, the study emphasizes the importance of early intervention. Leqvio®, administered biannually, demonstrated a marked improvement in cholesterol management among ASCVD patients, including those with a history of ASCVD-related events. This underscores the drug’s potential as a critical component in cardiovascular disease management strategies.
According to the study, patients who added Leqvio® to their existing statin therapy observed a significant reduction in LDL-C levels. This is particularly noteworthy for patients who previously struggled to reach their cholesterol goals through statin therapy alone, highlighting Leqvio®’s role in filling a vital treatment gap.
The results are seen as a significant advancement in the fight against cardiovascular disease, the leading cause of death globally. By effectively lowering LDL-C levels, a key risk factor for heart attacks and strokes, Leqvio® offers a new hope for patients at risk.
In summary, the integration of Leqvio® into treatment regimens could revolutionize the approach to managing cholesterol levels, particularly in ASCVD patients. This development marks a significant stride in Novartis’ commitment to addressing unmet medical needs in cardiovascular health.